Search

Your search keyword '"Lucini V"' showing total 41 results
Start Over Author "Lucini V" Publication Type Electronic Resources
41 results on '"Lucini V"'

1. Customizing antiangiogenesis therapy toward vessel normalization results in a long-term glioma growth control

Author

Bello, L, Colleoni, F, Sangiorgi, S, Lucini, V, Pannacci, M, Acerbi, F, Giussani, C, Carrabba, G, Gaini, S, Bikfalvi, A, Bello L., Colleoni F., Sangiorgi S., Lucini V., Pannacci M., Acerbi F., Giussani C., Carrabba G, Gaini S., Bikfalvi A., Bello, L, Colleoni, F, Sangiorgi, S, Lucini, V, Pannacci, M, Acerbi, F, Giussani, C, Carrabba, G, Gaini, S, Bikfalvi, A, Bello L., Colleoni F., Sangiorgi S., Lucini V., Pannacci M., Acerbi F., Giussani C., Carrabba G, Gaini S., and Bikfalvi A.

Published
2006

2. Human skin-derived stem cells inhibit brain tumor growth

Author

Acerbi, F, Giussani, C, Pisati, F, Carrabba, G, Belicchi, M, Lucini, V, Gaini, S, Bikfalvi, A, Torrente, Y, Bello, L, Acerbi F, Giussani C, Pisati F, Carrabba G, Belicchi M, Lucini V, Gaini SM, Bikfalvi A, Torrente Y, Bello L, Acerbi, F, Giussani, C, Pisati, F, Carrabba, G, Belicchi, M, Lucini, V, Gaini, S, Bikfalvi, A, Torrente, Y, Bello, L, Acerbi F, Giussani C, Pisati F, Carrabba G, Belicchi M, Lucini V, Gaini SM, Bikfalvi A, Torrente Y, and Bello L

Published
2005

3. Tailoring of anti angiogenic therapies to tumor stage improves therapeutic efficacy in mouse models of human gliomas

Author

Giussani, C, Acerbi, F, Sangiorgi, S, Colleoni, F, Carrabba, G, Lucini, V, Pannacci, M, Tomei, G, Gaini, S, Bikfalvi, A, Bello, L, Giussani C, Acerbi F, Sangiorgi S, Colleoni F, Carrabba G, Lucini V, Pannacci M, Tomei G, Gaini SM, Bikfalvi A, Bello L, Giussani, C, Acerbi, F, Sangiorgi, S, Colleoni, F, Carrabba, G, Lucini, V, Pannacci, M, Tomei, G, Gaini, S, Bikfalvi, A, Bello, L, Giussani C, Acerbi F, Sangiorgi S, Colleoni F, Carrabba G, Lucini V, Pannacci M, Tomei G, Gaini SM, Bikfalvi A, and Bello L

Published
2005

4. In vivo targeting ability of human glioblastoma by human skin-derived stem cells

Author

Pluderi, M, Costa, F, Giussani, C, Carrabba, G, Lucini, V, Caronzolo, D, Carroll, R, Bikfalvi, A, Torrente, Y, Bello, L, Pluderi M, Costa F, Giussani C, Carrabba G, Lucini V, Caronzolo D, Carroll R, Bikfalvi A, Torrente Y, Bello L, Pluderi, M, Costa, F, Giussani, C, Carrabba, G, Lucini, V, Caronzolo, D, Carroll, R, Bikfalvi, A, Torrente, Y, Bello, L, Pluderi M, Costa F, Giussani C, Carrabba G, Lucini V, Caronzolo D, Carroll R, Bikfalvi A, Torrente Y, and Bello L

Published
2003

5. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo (vol 63, pg 2499, 2003)

Author

Giussani C, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Costa, F, Minotti, M, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Bello, L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Costa F, Minotti M, Tomei G, Villani R, Carroll RS, Bikfalvi A, Bello L, Giussani C, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Costa, F, Minotti, M, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Bello, L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Costa F, Minotti M, Tomei G, Villani R, Carroll RS, Bikfalvi A, and Bello L

Published
2003

6. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models

Author

Pisati, F, Belicchi, M, Acerbi, F, Marchesi, C, Giussani, C, Gavina, M, Javerzat, S, Hagedorn, M, Carrabba, G, Lucini, V, Gaini, S, Bresolin, N, Bello, L, Bikfalvi, A, Torrente, Y, Gaini, SM, Torrente, Y., GIUSSANI, CARLO GIORGIO, Pisati, F, Belicchi, M, Acerbi, F, Marchesi, C, Giussani, C, Gavina, M, Javerzat, S, Hagedorn, M, Carrabba, G, Lucini, V, Gaini, S, Bresolin, N, Bello, L, Bikfalvi, A, Torrente, Y, Gaini, SM, Torrente, Y., and GIUSSANI, CARLO GIORGIO

Abstract

Glioblastomas represent an important cause of cancer-related mortality with poor survival. Despite many advances, the mean survival time has not significantly improved in the last decades. New experimental approaches have shown tumor regression after the grafting of neural stem cells and human mesenchymal stem cells into experimental intracranial gliomas of adult rodents. However, the cell source seems to be an important limitation for autologous transplantation in glioblastoma. In the present study, we evaluated the tumor targeting and antitumor activity of human skin-derived stem cells (hSDSCs) in human brain tumor models. The hSDSCs exhibit tumor targeting characteristics in vivo when injected into the controlateral hemisphere or into the tail vein of mice. When implanted directly into glioblastomas, hSDSCs distributed themselves extensively throughout the tumor mass, reduced tumor vessel density, and decreased angiogenic sprouts. In addition, transplanted hSDSCs differentiate into pericyte cell and release high amounts of human transforming growth factor-beta1 with low expression of vascular endothelial growth factor, which may contribute to the decreased tumor cell invasion and number of tumor vessels. In long-term experiments, the hSDSCs were also able to significantly inhibit tumor growth and to prolong animal survival. Similar behavior was seen when hSDSCs were implanted into two different tumor models, the chicken embryo experimental glioma model and the transgenic Tyrp1-Tag mice. Taken together, these data validate the use of hSDSCs for targeting human brain tumors. They may represent therapeutically effective cells for the treatment of intracranial tumors after autologous transplantation

Published
2007

13. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma

Author

Bello, L, Lucini, V, Costa, F, Pluderi, M, Giussani, C, Acerbi, F, Carrabba, G, Pannacci, M, Caronzolo, D, Grosso, S, Shinkaruk, S, Colleoni, F, Canron, X, Tomei, G, Deleris, G, Bikfalvi, A, Bikfalvi, A., GIUSSANI, CARLO GIORGIO, Bello, L, Lucini, V, Costa, F, Pluderi, M, Giussani, C, Acerbi, F, Carrabba, G, Pannacci, M, Caronzolo, D, Grosso, S, Shinkaruk, S, Colleoni, F, Canron, X, Tomei, G, Deleris, G, Bikfalvi, A, Bikfalvi, A., and GIUSSANI, CARLO GIORGIO

Abstract

PURPOSE: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. EXPERIMENTAL DESIGN: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). RESULTS: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. CONCLUSIONS: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.

Published
2004

14. Human skin-derived stem cells inhibit brain tumor growth

Author

Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, Bello, L, Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, and Bello, L

Published
2004

16. Human Skin-Derived Stem Cells Inhibit Brain Tumor Growth

Author

Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, Bello, L, Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, and Bello, L

Published
2004

17. Human skin-derived stem cells inhibit brain tumor growth

Author

Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, Bello, L, Pisati F, Belicchi M, Acerbi, F, Giussani, C, Carrabba, G, Costa, F, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, Bello, L, Pisati F, and Belicchi M

Published
2004

18. Human skin-derived stem cells inhibit brain tumor growth.

Author

Giussani, C, Carrabba, G, Pluderi, M, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, Bello, L, Giussani, C, Carrabba, G, Pluderi, M, Pisati, F, Belicchi, M, Lucini, V, Bikfalvi, A, Torrente, Y, and Bello, L

Published
2004

19. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo

Author

Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Costa, F, Minotti, M, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Bello, L, GIUSSANI, CARLO GIORGIO, Bello, L., Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Costa, F, Minotti, M, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Bello, L, GIUSSANI, CARLO GIORGIO, and Bello, L.

Abstract

The systemic administration of endogenous inhibitors significantly reduced the growth of human glioma in vivo, but required the production of a large amount of biologically active protein. In this study we reduced the amount of protein needed and optimized the therapeutical response by delivering the endogenous inhibitors locally into the brain by osmotic minipumps. Human hemopexin fragment of MMP-2 or COOH-terminal fragment of platelet factor-4 were delivered locally and continuously into the brain of mice implanted intracranially with glioma cells, by osmotic minipumps connected to an intracranial catheter. Local delivery of human hemopexin fragment of MMP-2 and COOH-terminal fragment of platelet factor-4 significantly inhibited the growth of well-established malignant glioma in nude and BALB/C mice. When the inhibitors were given at the same concentration, the efficacy of the local delivery was much higher than that reached with the systemic administration, both when the inhibitor was administered daily or continuously by s.c. minipumps. Moreover, the local delivery reduced the amount of protein needed to reach a significant therapeutic response. Intracerebral delivery maintained a long-term control of glioma growth and inhibited glioma recurrence in a surgical resection model. Treatment showed no side effects. Histochemical analysis of tumors showed that the tumor growth inhibition was the result of a decrease in tumor vasculature and a change in tumor vessel morphology. Our data demonstrate that local intracerebral delivery of endogenous inhibitors effectively inhibits malignant glioma growth and reduces the amount of protein needed to reach a therapeutical response.

Published
2003

20. IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo

Author

Bello, L, Lucini, V, Giussani, C, Carrabba, G, Pluderi, M, Scaglione, F, Tomei, G, Villani, R, Black, P, Bikfalvi, A, Carroll, R, Giussani, CG, Carroll, R., Bello, L, Lucini, V, Giussani, C, Carrabba, G, Pluderi, M, Scaglione, F, Tomei, G, Villani, R, Black, P, Bikfalvi, A, Carroll, R, Giussani, CG, and Carroll, R.

Abstract

OBJECTIVE: The biological features of malignant gliomas include high cell proliferation, extensive local infiltration of tumor cells into normal brain, and marked neovascularization. alphavbeta3 integrin is highly expressed in malignant gliomas and plays a role in glioma growth. This article investigates, the in vitro and in vivo effects of a synthetic alphavbeta3 integrin inhibitor called IS201 on human malignant gliomas. METHODS: The in vitro effects of IS201. were studied by performing adhesion assays, competition studies, semi-in vivo angiogenic assays, and migration and proliferation assays. For the in vivo experiments, IS201 was administered systemically in nude mouse intracranial and subcutaneous malignant glioma models. RESULTS: IS201 reacted selectively to alphavbeta3 integrin in glioma cells and tissues. In vitro, IS201 strongly inhibited angiogenesis and simultaneously exhibited potent antimitotic and antimigratory effects on numerous tumor and endothelial cell lines. In addition, at high concentrations, IS201 induced endothelial and tumor cell apoptosis. In vivo, when IS201 was administered intraperitoneally in subcutaneous and intracranial nude mouse glioma models, it potently reduced malignant glioma growth. Inhibition levels of 76 and 82% were observed at concentrations of 1 and 5 mg/kg, respectively, in the U87 intracranial model. The suppression of tumor growth is associated with a decrease in tumor vascularity, an increase in apoptosis, and a decrease in tumor cell proliferation. CONCLUSION: This work expands the understanding of the effects of anti-alphavbeta3 integrin inhibitors on malignant gliomas. In addition to direct proapoptotic and antiangiogenic effects, IS201 inhibits tumor and endothelial cell proliferation and migration, resulting in a potent inhibition of glioma growth in vivo

Published
2003

21. Long-term inhibition of glioma growth by systemic administration of human PEX

Author

Pluderi, M, Lucini, V, Caronzolo, D, Pannacci, M, Costa, F, Carrabba, G, Giussani, C, Grosso, S, Colleoni, F, Scaglione, F, Villani, R, Bikfalvi, A, Bello, L, Bello, L., GIUSSANI, CARLO GIORGIO, Pluderi, M, Lucini, V, Caronzolo, D, Pannacci, M, Costa, F, Carrabba, G, Giussani, C, Grosso, S, Colleoni, F, Scaglione, F, Villani, R, Bikfalvi, A, Bello, L, Bello, L., and GIUSSANI, CARLO GIORGIO

Abstract

The growth of gliomas depends on the balance of factors stimulating or inhibiting angiogenesis, tumor cell invasion and proliferation. The administration of endogenous inhibitors to experimental human gliomas in animal models resulted in a significant inhibition of tumor growth. It is becoming apparent that resistance can develop over time to many types of endogenous inhibitors and seems to be influenced by the tumor type and system of delivery.

Published
2003

24. Inhibition of Glioma Growth by a Synthetic Inhibitor of VEGF

Author

Costa, F, Pluderi, M, Giussani, C, Carrabba, G, Lucini, V, Caronzolo, D, Pannacci, M, Zilberberg, L, Hagedorn, M, Bikfalvi, A, Bello, L, Costa, F, Pluderi, M, Giussani, C, Carrabba, G, Lucini, V, Caronzolo, D, Pannacci, M, Zilberberg, L, Hagedorn, M, Bikfalvi, A, and Bello, L

Published
2003

26. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors

Author

Bello, L, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Tomei, G, Villani, R, Scaglione, F, Carroll, R, Bikfalvi, A, Bikfalvi, A., GIUSSANI, CARLO GIORGIO, Bello, L, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Tomei, G, Villani, R, Scaglione, F, Carroll, R, Bikfalvi, A, Bikfalvi, A., and GIUSSANI, CARLO GIORGIO

Abstract

Glioma recurrences develop at the borders of the surgical cavity and are the main cause of their poor prognosis. There are no therapeutic advances to reduce the incidence of recurrence or animal models that closely mimic the clinical scenario to evaluate novel therapeutics. This work investigates the efficacy of endogenous inhibitors, in preventing the recurrence of human malignant gliomas, in a newly developed animal model of glioma surgical resection. We developed a nude mice model in which human glioma xenografts were microsurgically removed. After surgery, small islets of tumor cells persisted in the normal brain parenchyma, grew, and formed a recurrence. As inhibitors we used PEX and a fragment of platelet factor 4 (PF-4/CTF), which were administered systemically on a daily basis or in metronomic combination with chemotherapy for 120 days. Treatment was started 1 or 15 days after tumor removal. PEX or PF-4/CTF produced a significant improvement in survival, and delayed the appearance of glioma recurrence. Survival of animals that received daily PEX or PF-4/CTF was similar to that of animals that received metronomic PEX or PF-4/CTF and chemotherapy, respectively. The effect of treatment was dependent on the time at which the treatment was initiated. The highest level of inhibition was observed when the treatment was administered 1 day after surgical resection and when PEX was used as the inhibitor (120 days versus 35 days of the control). Tumors treated with PEX or PF-4/CTF were small and well delineated, with few vessels. Postsurgical administration of PEX or PF-4/CTF significantly reduces the incidence human malignant glioma recurrences for a long period of time.

Published
2002

28. Long-term inhibition of human malignant glioma growth by human PEX

Author

Pluderi, M, Lucini, V, Carrabba, G, Giussani, C, Pannacci, M, Caronzolo, D, Villani, R, Black, P, Carroll, R, Bikfalvi, A, Bello, L, Carroll, RS, Pluderi, M, Lucini, V, Carrabba, G, Giussani, C, Pannacci, M, Caronzolo, D, Villani, R, Black, P, Carroll, R, Bikfalvi, A, Bello, L, and Carroll, RS

Published
2002

30. Inhibition of Glioma Growth by Endogenous Inhibitors

Author

Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Villani, R, Bikfalvi, A, Bello, L, Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Villani, R, Bikfalvi, A, and Bello, L

Published
2002

32. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

Author

Bello, L, Carrabba, G, Giussani, C, Lucini, V, Cerutti, F, Scaglione, F, Landré, J, Pluderi, M, Tomei, G, Villani, R, Carroll, R, Black, P, Bikfalvi, A, Bikfalvi, A., GIUSSANI, CARLO GIORGIO, Bello, L, Carrabba, G, Giussani, C, Lucini, V, Cerutti, F, Scaglione, F, Landré, J, Pluderi, M, Tomei, G, Villani, R, Carroll, R, Black, P, Bikfalvi, A, Bikfalvi, A., and GIUSSANI, CARLO GIORGIO

Abstract

This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo

Published
2001

33. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2

Author

Bello, L, Lucini, V, Carrabba, G, Giussani, C, Machluf, M, Pluderi, M, Nikas, D, Zhang, J, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Black, P, Black, P., GIUSSANI, CARLO GIORGIO, Bello, L, Lucini, V, Carrabba, G, Giussani, C, Machluf, M, Pluderi, M, Nikas, D, Zhang, J, Tomei, G, Villani, R, Carroll, R, Bikfalvi, A, Black, P, Black, P., and GIUSSANI, CARLO GIORGIO

Abstract

Angiogenesis, tumor cell proliferation, and migration are the hallmarks of solid tumors, such as gliomas. This study demonstrates that a fragment derived from the autocatalytic digestion of matrix metalloproteinase (MMP)-2, called PEX, acts simultaneously as an inhibitor of glioma angiogenesis, cell proliferation, and migration. PEX is detected in the cultured medium of various human glioma, endothelial, breast, and prostate carcinoma cell lines. PEX is purified from the medium of glioma cell lines by chromatography, where PEX is constitutively expressed as a free and a TIMP-2-bound form. In human glioma tissue, PEX expression correlates with histological subtype and grade and with alpha v beta 3 integrin expression to which it is bound. Systemic administration of PEX to s.c. and intracranial human glioma xenografts results in a 99% suppression of tumor growth with no signs of toxicity. Thus, PEX is a very promising candidate for the treatment of human malignant gliomas

Published
2001

37. IS201, a specific alphavBeta3 inhibitor, reduces glioma growth in Vivo

Author

Bello, L, Pluderi, M, Carrabba, G, Giussani, C, Lucini, V, Tomei, G, Villani, R, Bikfalvi, A, Carroll, R, Black, P, Carroll, RS, Bello, L, Pluderi, M, Carrabba, G, Giussani, C, Lucini, V, Tomei, G, Villani, R, Bikfalvi, A, Carroll, R, Black, P, and Carroll, RS

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results